Reducing sphingolipid de novo synthesis by myriocin, an inhibitor of serine palmitoyltransferase (SPT), the first and rate-limiting enzyme of the sphingolipid biosynthesis pathway, counteracts DMD-related loss in muscle function in the mdx mouse model of muscular dystrophy. This evidence concerns the gene AGXT and Duchenne muscular dystrophy.